---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-082211"
form_type: "8-K"
ticker: "TAOX"
cik: "0001571934"
company_name: "TAO Synergies Inc."
filed_at: "2023-07-19T23:59:59+00:00"
generated_at: "2026-06-13T06:22:40.422704+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis

## Summary
- Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.
- Trial expected to commence in Q4 2023 at Cleveland Clinic's Mellen Center for Multiple Sclerosis.
- Synaptogenix had approximately $35.8M in cash as of March 31, 2023, sufficient to fund the trial and other developments.
- Bryostatin-1 targets synaptic regeneration and anti-inflammatory pathways; cognitive impairment is a key unmet need in MS.

## SEC filing metadata
- accession: 0001104659-23-082211
- form_type: 8-K
- ticker: TAOX
- cik: 0001571934
- company_name: TAO Synergies Inc.
- filed_at: 2023-07-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/0001104659-23-082211-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1571934/000110465923082211/tm2321611d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-082211
- JSON: https://secwatch.observer/filing/0001104659-23-082211.json
- Plain text: https://secwatch.observer/filing/0001104659-23-082211.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.